Citation: | LI Wenliu, XING Chunyan, LI Qin, ZHAO Yongli, HE Chunlin, WANG Lizhuo, GAO Jialin. One case of diabetic nephropathy treated with multi-glycosides of tripterygium wilfordii and efficacy analysis of its anti-inflammatory and anti-fibrosis[J]. Chinese Journal of General Practice, 2024, 22(3): 530-533. doi: 10.16766/j.cnki.issn.1674-4152.003442 |
[1] |
董兴刚, 安增梅. 雷公藤治疗糖尿病肾病临床应用的研究进展[J]. 世界中医药, 2019, 14(8): 2233-2236. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA201908067.htm
DONG X G, AN Z M. Research progress of clinical application of radix tripterygii wilfordii in the treatment of diabetic nephropathy[J]. World Chinese Medicine, 2019, 14(8): 2233-2236. https://www.cnki.com.cn/Article/CJFDTOTAL-SJZA201908067.htm
|
[2] |
北京大学医学系糖尿病肾脏病专家共识协作组. 糖尿病肾脏病诊治专家共识[J]. 中华医学杂志, 2020, 100(4): 247-260.
Diabetic Nephropathy Expert Consensus Cooperation Group of Peking University School of Medicine. Diabetic nephropathy diagnosis and treatment expert consensus[J]. Natl Med J Chin, 2020, 100(4): 247-260.
|
[3] |
SELBY N, MTAAL M W. An updated overview of diabetic nephropathy: diagnosis, prognosis, treatment goals and latest guidelines[J]. Diabetes Obes Metab, 2020, 22(Suppl 1): 3-15.
|
[4] |
SAWAF H, THOMAS G, TALIERCIO J J, et al. Therapeutic advances in diabetic nephropathy[J]. J Clin Med, 2022, 11(2): 378. DOI: 10.3390/jcm11020378.
|
[5] |
应一樱, 陈洁包, 蓓艳. 维生素D联合西格列汀对2型糖尿病肾病患者尿蛋白水平、骨密度和骨代谢的影响[J]. 中华全科医学, 2019, 17(5): 797-800, 840. doi: 10.16766/j.cnki.issn.1674-4152.000795
YING Y Y, CHEN J, BAO B Y. Effects of vitamin D combined with sitagliptin on urinary protein level, bone mineral density and bone metabolism in patients with type 2 diabetic nephropathy[J]. Chinese Journal of General Practice, 2019, 17(5): 797-800, 840. doi: 10.16766/j.cnki.issn.1674-4152.000795
|
[6] |
WANNER C, COOPER M E, JOHANSEN O E, et al. Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial[J]. Clin Kidney J, 2021, 14(1): 226-236. doi: 10.1093/ckj/sfaa225
|
[7] |
DONATE-CORREA J, SANCHEZ-NINO M D, GONZALEZ-LUIS A, et al. Repurposing drugs for highly prevalent diseases: pentoxifylline, an old drug and a new opportunity for diabetic kidney disease[J]. Clin Kidney J, 2022, 15(12): 2200-2213. doi: 10.1093/ckj/sfac143
|
[8] |
邱文超, 郭雪梅, 朱穆朗玛, 等. 中医药治疗糖尿病肾病研究进展[J]. 辽宁中医药大学学报, 2021, 23(4): 157-162. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB202104035.htm
QIU W C, GUO X M, ZHU M L M, et al. Research progress of traditional Chinese medicine in treating diabetic nephropathy[J]. J Liaoning Univ Tradit Chin Med, 2021, 23(4): 157-162. https://www.cnki.com.cn/Article/CJFDTOTAL-LZXB202104035.htm
|
[9] |
王萧钧, 李介珍, 王莉红, 等. 黄葵胶囊联合ACEI/ARB治疗糖尿病肾病的meta分析[J]. 现代医药卫生, 2021, 37(11): 1814-1817. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202111005.htm
WANG X J, LI J Z, WANG L H, et al. Meta-analysis of Huangkui capsule combined with ACEI/ARB in the treatment of diabetic nephropathy[J]. J Mod Med Health, 2021, 37(11): 1814-1817. https://www.cnki.com.cn/Article/CJFDTOTAL-XYWS202111005.htm
|
[10] |
左建娇, 王津, 魏萱, 等. 雷公藤多苷片联合百令胶囊治疗Ⅳ期糖尿病肾病的临床效果[J]. 解放军医药杂志, 2022, 34(6): 131-134. https://www.cnki.com.cn/Article/CJFDTOTAL-HBGF202206032.htm
ZUO J J, WANG J, WEI X, et al. Clinical effect of tripterygium glycosides tablets combined with Bailing capsules in the treatment of stage Ⅳ diabetic nephropathy[J]. Med & Pharm J Chin PLA, 2022, 34(6): 131-134. https://www.cnki.com.cn/Article/CJFDTOTAL-HBGF202206032.htm
|
[11] |
WANG L, WANG Z, YANG Z, et al. Study of the active components and molecular mechanism of tripterygium wilfordii in the treatment of diabetic nephropathy[J]. Front Mol Biosci, 2021, 8: 664416. DOI: 10.3389/fmolb.2021.664416.
|
[12] |
LIU P, ZHANG J, WANG Y, et al. The active compounds and therapeutic target of Tripterygium wilfordii Hook. f. in attenuating proteinuria in diabetic nephropathy: a review[J]. Front Med(Lausanne), 2021, 8: 747922. DOI: 10.3389/fmed.2021.747922.
|
[13] |
程亚清, 曲海顺, 张献之, 等. 雷公藤多苷辅助治疗糖尿病肾病的Meta分析[J]. 中国中西医结合肾病杂志, 2022, 23(2): 133-139. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB202202006.htm
CHENG Y Q, QU H S, ZHANG X Z, et al. Meta-analysis of tripterygium wilfordii polyglycosides in adjuvant treatment of diabetic nephropathy[J]. Chin J Integr Tradit West Med Nephr, 2022, 23(2): 133-139. https://www.cnki.com.cn/Article/CJFDTOTAL-JXSB202202006.htm
|
[14] |
LENGNAN X, BAN Z, HAITAO W, et al. Tripterygium wilfordii Hook F treatment for stage Ⅳ diabetic nephropathy: protocol for a prospective, randomized controlled trial[J]. Biomed Res Int, 2020, 2020: 9181037. DOI: 10.1155/2020/9181037.
|
[15] |
孙智梅, 刘妍. 雷公藤多苷片联合SGLTs抑制剂治疗糖尿病肾病患者的效果[J]. 中国医药科学, 2022, 12(15): 104-107. https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX202215025.htm
SUN Z M, LIU Y. The effect of tripterygium glycosides tablets combined with SGLTs inhibitors in the treatment of patients with diabetic nephropathy[J]. China Medicine and Pharmacy, 2022, 12(15): 104-107. https://www.cnki.com.cn/Article/CJFDTOTAL-GYKX202215025.htm
|
[16] |
马爱景, 姚曦. 雷公藤多苷片联合钠-葡萄糖协同转运蛋白2抑制剂对糖尿病肾病肾功能及蛋白尿水平影响研究[J]. 中华中医药学刊, 2020, 38(8): 200-203. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202008048.htm
MA A J, YAO X. Study on the effect of tripterygium glycosides tablets combined with sodium-glucose cotransporter 2 inhibitors on renal function and proteinuria in diabetic nephropathy[J]. Chin J Tradit Chin Med Pharm, 2020, 38(8): 200-203. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202008048.htm
|
[17] |
姜淼, 张海波, 张霞, 等. 雷公藤多苷不良反应及配伍减毒研究进展[J]. 中华中医药学刊, 2021, 39(5): 64-66. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202105017.htm
JIANG M, ZHANG H B, ZHANG X, et al. Advances in research on adverse reactions of tripterygium wilfordii polyglycosides and compatibility attenuation[J]. Chin J Tradit Chin Med Pharm, 2021, 39(5): 64-66. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS202105017.htm
|